The Two Vaccines Have Different Basic Structures — How Recombinant and Live Vaccines Work
Two vaccines are currently used to prevent shingles: Shingrix (a recombinant vaccine) and Zostavax (a live attenuated vaccine). Both were developed to prevent the same disease, but they differ in everything from the form of the antigen to how they trigger immunity and who can receive them. Rather than taking the approach that "either one works as long as you get vaccinated once," it makes more sense to check your age and immune status first before choosing a vaccine.
Shingrix is a recombinant subunit vaccine made from glycoprotein E (gE), one of the surface proteins of the varicella-zoster virus (VZV, the virus that causes chickenpox in childhood and then lies dormant in nerve ganglia). It contains no live virus. Instead, it includes an adjuvant called AS01B, which induces both strong cell-mediated immunity and antibody responses that the antigen alone would have difficulty producing (Lim Delwyn Zhi Jie et al., 2025).
Zostavax administers the live attenuated virus itself. This is the classical approach in which the virus replicates in a limited way within the body and stimulates the immune system. It has generally been safe in healthy adults, though adverse reactions such as chickenpox-like rashes at the vaccination site have been reported. For people whose immune system isn't functioning normally, this "limited replication" becomes a major risk factor. In patients undergoing cancer treatment or taking immunosuppressants after an organ transplant, cases of disseminated varicella infection—in which the attenuated virus spreads without being controlled—have been reported, which is why the vaccine is generally contraindicated in immunocompromised individuals (Patil Anant et al., 2022).
In the clinic, this difference turns out to be less widely known than one might expect. A frequent question is, "Isn't Zostavax more convenient since one dose is enough?" It's worth pointing out that behind this convenience lies a limitation inherent to the vaccine platform itself.
Prevention Effectiveness and Duration — Comparing Clinical Data
When comparing vaccines, two things matter most: how well they prevent disease, and how long that protection lasts. The two vaccines show a clear difference on both measures.
Shingrix showed an overall vaccine efficacy of about 97.2% in large-scale clinical trials (Lim Delwyn Zhi Jie et al., 2025). Immune response typically weakens with age, and vaccine effectiveness tends to decline along with it, but Shingrix's drop-off is relatively small. This is interpreted as a result of the AS01B adjuvant helping to stimulate an immune system that has grown less responsive with aging. These are clinical trial results, and individual differences may occur.
Zostavax has reported prevention rates of about 51% in people 60 and older and about 38% in people 70 and older (Shingles Prevention Study). That amounts to roughly cutting cases in half, but the prevention rate drops noticeably once patients move into their 70s. The duration of protection also differs substantially. Zostavax's immune effect is reported to decline meaningfully starting around 5 years after vaccination, while Shingrix maintains relatively good protection up to around 10 years. That said, reports are also emerging that Shingrix's protection may gradually decline over time as well.
There's one measure that matters even more from a patient's standpoint: how well a vaccine prevents postherpetic neuralgia (PHN) — the neuropathic pain that persists after the rash has cleared. Patients with PHN are seen often in the clinic. The rash is gone in 2 to 3 weeks, but the pain can continue for 6 months, a year, or even several years. Combining antidepressants, anticonvulsants, and nerve block procedures often still fails to achieve satisfactory control, and response to treatment varies from person to person. Shingrix is reported to prevent more than 91% of PHN (pooled analysis of ZOE-50 and ZOE-70). Beyond simply reducing how often shingles occurs, this matters because it blocks the path into chronic neuropathic pain. These are clinical trial results, and individual differences may occur.
Looking at the numbers alone, the difference is clear. That said, the two vaccines' clinical trials differed in population composition and follow-up duration, so direct comparison has its limits — a point worth keeping in mind.
Differences in Who Gets Vaccinated and How
For a vaccine, who can receive it and how matters as much as its effectiveness. The two vaccines differ in this respect.
Shingrix targets adults aged 50 and older as its primary group and requires two doses. The second dose typically follows the first by 2 to 6 months, though the schedule may be adjusted under a physician's judgment depending on the patient's situation, such as timing around cancer treatment. Needing two visits can feel like a burden, but Shingrix offers a major advantage: it can be given to immunocompromised patients as well. For patient groups who cannot receive live vaccines — those undergoing chemotherapy, hematopoietic stem cell transplantation, immunosuppressive therapy after organ transplantation, or immunosuppressive treatment for autoimmune disease — a recombinant vaccine containing no live virus becomes nearly the only option (Lim Delwyn Zhi Jie et al., 2025).
Zostavax, under its Korean approval, is given as a single dose to those aged 60 and older. The simplicity of finishing in one visit is an advantage, but its use is restricted in principle for immunocompromised individuals. People in their 50s who want to start prevention early, or those undergoing immunosuppressive treatment, are not candidates for this vaccine from the outset.
What about those who have already had shingles once? Having had it once does not mean it will never recur. The recurrence rate is high enough that it cannot be ignored, so even with a past history of shingles, Shingrix vaccination is recommended after a certain period has passed. Likewise, those who received Zostavax in the past can later receive Shingrix as an additional vaccination once enough time has elapsed. Getting vaccinated once isn't the end of the matter — it's worth revisiting whether a booster is needed after time has passed.
Here is a question that comes up often in the clinic: "Having to get two doses is inconvenient — can't I just get one and be done?" Shingrix only builds sufficient protective effect once the second dose is completed. If scheduling is difficult, it makes more sense to start the series at a time when you can realistically complete both doses.
Factors to Consider When Choosing Between the Two Vaccines
In actual clinical practice, choosing a vaccine means weighing four factors together: age, immune status, cost, and vaccination history.
Let's start with age. For someone in their early 50s who wants to begin prevention early, Shingrix is an option given its approved age range. In the 60s and 70s, the incidence of shingles itself rises sharply, and so does the risk that the rash, once it clears, progresses to nerve pain. The incidence and severity of postherpetic neuralgia clearly increase with age, so the clinical rationale for choosing a vaccine with reported preventive efficacy grows stronger as patients get older. It's also worth noting that the gap in preventive efficacy between the two vaccines is largest in people aged 70 and above.
Immune status essentially decides the choice. For patients undergoing cancer treatment, taking immunosuppressants for rheumatoid arthritis or inflammatory bowel disease, or receiving immune modulation after an organ transplant, a live attenuated vaccine is difficult to recommend safely. In these cases, the recombinant vaccine is effectively the only usable option (Lim Delwyn Zhi Jie et al., 2025). Some patients come in looking for "a vaccine that only takes one dose" without realizing they are on immunosuppressive treatment, so checking current medications and underlying conditions must always come before vaccination.
Cost can't be ignored. Shingrix requires two doses, and its per-dose cost also tends to be higher than Zostavax. Added up, the financial burden is indeed greater. That said, if the protection lasts longer and comes with PHN prevention, it can help to think in terms of "years of protection" rather than cost per dose. This depends on each patient's financial situation and priorities.
Vaccination history is a surprisingly common thing people overlook. Many assume that because they got Zostavax a few years ago, there's nothing more to do, but since the immune effect declines over time, an additional Shingrix dose is possible after an appropriate interval. People who had shingles in the past and recovered can also work out a new vaccination plan to prevent recurrence.
One more thing worth adding is the weight of postherpetic neuralgia. Chronic pain that persists for months to years after the rash clears chips away at sleep, appetite, going outside, and daily activities overall. Nerve block procedures and medication may help reduce the intensity, but they cannot reverse the condition once it has occurred. Vaccination is one medical option for lowering the likelihood of shingles and its complications. Individual responses may vary, so please consult a medical professional.
Key Takeaways
Shingrix (a recombinant vaccine) and Zostavax (a live vaccine) prevent the same disease, but they work in fundamentally different ways. Shingrix combines a viral protein component with an adjuvant to trigger an immune response, while Zostavax uses a live attenuated virus itself.
In clinical data, Shingrix showed an overall vaccine efficacy of about 97.2%, with protection reported to be relatively well maintained for up to 10 years (Lim Delwyn Zhi Jie et al., 2025). Zostavax offers the convenience of a single dose, but its reported prevention rate is about 51% in people aged 60 and older and about 38% in those 70 and older, with effectiveness declining around the 5-year mark. These figures come from clinical trials, and individual results may vary.
The target populations also differ. Shingrix is given as two doses to people aged 50 and older and can be used in immunocompromised patients, while Zostavax is given as a single dose to people aged 60 and older but is generally restricted in immunocompromised individuals.
Deciding which vaccine suits you ultimately requires weighing age, immune status, underlying conditions, and past vaccination history together. The burden of postherpetic neuralgia, a potential complication of shingles, is too significant to base a decision solely on which option is "a single shot and done" or has "a lower cost." The safest approach is to work out a vaccination plan together with a healthcare provider who knows your situation best.
This content is provided for medical information purposes, and outcomes may vary depending on individual conditions. Please consult a specialist for accurate diagnosis and treatment.
References
- Lim Delwyn Zhi Jie, Tey Hong Liang, Salada Brenda Mae Alferez (2025). Herpes Zoster and Post-Herpetic Neuralgia-Diagnosis, Treatment, and Vaccination Strategies.. Pathogens. PMID: 39057822
- Patil Anant, Goldust Mohamad, Wollina Uwe (2022). Herpes zoster: A Review of Clinical Manifestations and Management.. Viruses. PMID: 35215786
- Adriaansen Elisabeth J M, Jacobs Julien G, Vernooij Lisette M (2025). 8. Herpes zoster and post herpetic neuralgia.. Pain Pract. PMID: 39364882
Frequently Asked Questions
Q. What's the difference between Shingrix and Zostavax?
The biggest difference lies in the vaccine's composition and the number of doses required. Shingrix is a recombinant vaccine made from a portion of a viral protein combined with an adjuvant, and it is given in two doses, while Zostavax is a single-dose vaccine that uses a live attenuated virus. Whether the vaccine can be given to immunosuppressed patients is also one of the key factors that sets the two vaccines apart.
Q. Can I get the shingles vaccine while taking immunosuppressants?
Live vaccines contain live virus and are generally avoided in people who are immunocompromised, due to safety concerns. Shingrix, however, is a recombinant vaccine, so vaccination may still be considered during cancer treatment, immunosuppressant therapy, and similar situations. That said, the right timing for vaccination can vary depending on your treatment schedule and immune status, so it's important to check with your doctor first.
Q. Do I still need Shingrix if I've already had shingles?
Having shingles once does not completely eliminate the risk of a recurrence. Immunity built up after natural infection can weaken over time, and recurrence is possible, particularly in older adults or those with a weakened immune system. For this reason, vaccination after a certain interval has passed is known to be clinically meaningful even for people who have already had shingles.
Q. Why do you need two doses of Shingrix?
Shingrix uses only a portion of the virus's proteins as an antigen rather than the whole virus, so two doses are needed to induce a sufficient immune response. The first dose primes the immune response, and the second dose, given 2 to 6 months later, strengthens it. Completing this two-dose schedule is necessary to expect the high preventive efficacy and long-term durability confirmed in clinical trials.
Q. What is the recommended age to get the shingles vaccine?
Under Korean approval standards, Shingrix can be administered from age 50 and up, while Zostavax is approved from age 60 and up. Both the incidence of shingles and the risk of postherpetic neuralgia rise noticeably with age, so if you're in your 50s, it's reasonable to consider the timing of vaccination based on your own immune status and overall health condition.